Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2015; 21(37): 10510-10527
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10510
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10510
Challenges of deciphering gastric cancer heterogeneity
Petra Hudler, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia
Author contributions: Hudler P designed, drafted, revised and approved the final version of the manuscript.
Conflict-of-interest statement: The author declares that there are no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Petra Hudler, PhD, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000 Ljubljana, Slovenia. petra.hudler@mf.uni-lj.si
Telephone: +386-1-5437663 Fax: +386-1-5437641
Received: April 26, 2015
Peer-review started: April 28, 2015
First decision: June 8, 2015
Revised: June 19, 2015
Accepted: August 31, 2015
Article in press: August 31, 2015
Published online: October 7, 2015
Peer-review started: April 28, 2015
First decision: June 8, 2015
Revised: June 19, 2015
Accepted: August 31, 2015
Article in press: August 31, 2015
Published online: October 7, 2015
Core Tip
Core tip: This article summarizes the evidence of heterogeneous gastric cancer molecular changes. Despite enormous research efforts, to date, none of the common DNA, RNA or protein aberrations have achieved the high sensitivities, specificities, and predictive values necessary for clinical utility. Complex interrogation schemes based on a systems medicine approach should be developed to determine effective therapeutic strategies and to identify molecular signatures that are specific for the early detection of gastric cancer and pre-malignant stomach lesions that could progress to malignant disease.